6-Feb-2026
TipRanks (Fri, 6-Feb 10:50 AM ET)
PRNewswire (Mon, 12-Jan 11:15 AM ET)
Biohaven’s Upcoming J.P. Morgan Conference Spotlight Highlights Strategic Pipeline Momentum
Market Chameleon (Wed, 7-Jan 3:39 AM ET)
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
PRNewswire (Wed, 7-Jan 7:00 AM ET)
PRNewswire (Wed, 24-Dec 1:00 PM ET)
PRNewswire (Thu, 11-Dec 7:00 AM ET)
PRNewswire (Thu, 13-Nov 4:05 PM ET)
Biohaven Prices $175 Million Public Offering—What Could This Mean for Future Growth?
Market Chameleon (Wed, 12-Nov 2:32 AM ET)
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
PRNewswire (Wed, 12-Nov 7:15 AM ET)
Biohaven Announces Proposed Public Offering of Common Shares
PRNewswire (Tue, 11-Nov 4:05 PM ET)
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Biohaven Ltd. Common Shares trades on the NYSE stock market under the symbol BHVN.
As of February 6, 2026, BHVN stock price climbed to $11.60 with 2,259,547 million shares trading.
BHVN has a beta of 1.66, meaning it tends to be more sensitive to market movements. BHVN has a correlation of 0.07 to the broad based SPY ETF.
BHVN has a market cap of $1.54 billion. This is considered a Small Cap stock.
Last quarter Biohaven Ltd. Common Shares reported $0 in Revenue and -$1.47 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.26.
In the last 3 years, BHVN traded as high as $62.21 and as low as $7.48.
The top ETF exchange traded funds that BHVN belongs to (by Net Assets): XBI, IWM, VXF, PINK, IBB.
BHVN has underperformed the market in the last year with a price return of -70.2% while the SPY ETF gained +15.1%. However, in the short term, BHVN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +36.0% vs +3.3% return in SPY. But in the last 2 weeks, BHVN shares have been beat by the market, returning -14.1% compared to an SPY return of +0.2%.
BHVN support price is $10.11 and resistance is $11.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHVN shares will trade within this expected range on the day.